BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 9125571)

  • 1. Activation, binding, and processing of complement component 3 (C3) by Blastomyces dermatitidis.
    Zhang MX; Klein B
    Infect Immun; 1997 May; 65(5):1849-55. PubMed ID: 9125571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.
    Kozel TR; Wilson MA; Pfrommer GS; Schlageter AM
    Infect Immun; 1989 Jul; 57(7):1922-7. PubMed ID: 2525113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of glucan and surface protein BAD1 in complement activation by Blastomyces dermatitidis yeast.
    Zhang MX; Brandhorst TT; Kozel TR; Klein BS
    Infect Immun; 2001 Dec; 69(12):7559-64. PubMed ID: 11705933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1.
    Nilsson-Ekdahl K; Nilsson B
    Eur J Immunol; 2001 Apr; 31(4):1047-54. PubMed ID: 11298329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
    Newman SL; Mikus LK
    J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast.
    Kozel TR; Pfrommer GS
    Infect Immun; 1986 Apr; 52(1):1-5. PubMed ID: 3514450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of C3 and binding to Aspergillus fumigatus conidia and hyphae.
    Kozel TR; Wilson MA; Farrell TP; Levitz SM
    Infect Immun; 1989 Nov; 57(11):3412-7. PubMed ID: 2680973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
    Mayes JT; Schreiber RD; Cooper NR
    J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opsonization of yeast cells with equine iC3b, C3b, and IgG.
    Gröndahl G; Johannisson A; Jensen-Waern M; Nilsson Ekdahl K
    Vet Immunol Immunopathol; 2001 Aug; 80(3-4):209-23. PubMed ID: 11457475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of complement by Treponema denticola.
    Schenkein HA; Berry CR
    J Dent Res; 1991 Feb; 70(2):107-10. PubMed ID: 1991867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans.
    Boxx GM; Nishiya CT; Kozel TR; Zhang MX
    Mol Immunol; 2009 Jan; 46(3):473-80. PubMed ID: 19038459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells.
    Olesen EH; Johnson AA; Damgaard G; Leslie RG
    Immunology; 1998 Feb; 93(2):177-83. PubMed ID: 9616366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of complement receptor type three and serum opsonins in the neutrophil response to yeast.
    Cain JA; Newman SL; Ross GD
    Complement; 1987; 4(2):75-86. PubMed ID: 3040333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of kinetics and target proteins for binding of human complement component C3 to the surface-exposed outer membrane of Chlamydia trachomatis serovar L2.
    Hall RT; Strugnell T; Wu X; Devine DV; Stiver HG
    Infect Immun; 1993 May; 61(5):1829-34. PubMed ID: 8478073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of complement C3 deposition and degradation on Klebsiella pneumoniae.
    Albertí S; Alvarez D; Merino S; Casado MT; Vivanco F; Tomás JM; Benedí VJ
    Infect Immun; 1996 Nov; 64(11):4726-32. PubMed ID: 8890232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential complement activation pathways promote C3b deposition on native and acetylated LDL thereby inducing lipoprotein binding to the complement receptor 1.
    Klop B; van der Pol P; van Bruggen R; Wang Y; de Vries MA; van Santen S; O'Flynn J; van de Geijn GJ; Njo TL; Janssen HW; de Man P; Jukema JW; Rabelink TJ; Rensen PC; van Kooten C; Cabezas MC
    J Biol Chem; 2014 Dec; 289(51):35421-30. PubMed ID: 25349208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staphylococcus aureus opsonization mediated via the classical and alternative complement pathways. A kinetic study using MgEGTA chelated serum and human sera deficient in IgG and complement factors C1s and C2.
    Verbrugh HA; Van Dijk WC; Peters R; Van Der Tol ME; Peterson PK; Verhoef J
    Immunology; 1979 Mar; 36(3):391-7. PubMed ID: 108204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of C3 deposition and degradation on bacterial surfaces after opsonization.
    Gordon DL; Rice J; Finlay-Jones JJ; McDonald PJ; Hostetter MK
    J Infect Dis; 1988 Apr; 157(4):697-704. PubMed ID: 3279137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans.
    Kozel TR; Weinhold LC; Lupan DM
    Infect Immun; 1996 Aug; 64(8):3360-8. PubMed ID: 8757876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Interactions of Serum and Bronchoalveolar Lavage Fluid Complement Proteins with Conidia of Airborne Fungal Pathogen Aspergillus fumigatus.
    Wong SSW; Daniel I; Gangneux JP; Jayapal JM; Guegan H; Dellière S; Lalitha P; Shende R; Madan T; Bayry J; Guijarro JI; Kuppamuthu D; Aimanianda V
    Infect Immun; 2020 Aug; 88(9):. PubMed ID: 32571987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.